Skin Cancer

Cutaneous Lymphoma in Dogs: Skin Cancer Warning Signs

By Emiel Maddens · Reviewed in consultation with licensed veterinary professionals · Updated June 2026 · 10 min read

Cutaneous Lymphoma in Dogs guide for dog owners

Key Takeaways

Cutaneous lymphoma is a form of cancer where malignant lymphocytes infiltrate the skin, producing chronic, progressive skin lesions that can mimic common dermatological conditions.
Epitheliotropic lymphoma (mycosis fungoides) involves T-lymphocytes that specifically target the epidermis, progressing through patch, plaque, and tumor stages.
Diagnostic delay is common because early lesions closely resemble allergic dermatitis, pyoderma, or seborrhea, and initial biopsies may be inconclusive.
Treatment options include retinoids, chemotherapy, radiation therapy, and supportive care, though the condition is generally considered incurable.
Prognosis varies, with some dogs maintaining a good quality of life for 1 to 2 years with appropriate management, particularly when diagnosed at an early stage.

Cutaneous lymphoma represents one of the most diagnostically challenging and emotionally difficult skin cancers that dogs can develop. Unlike most skin tumors that present as discrete masses easily detected by owners and veterinarians, cutaneous lymphoma infiltrates the skin in a diffuse pattern that can closely mimic common, treatable skin conditions for months or even years before the true diagnosis is established. The progressive nature of the disease, combined with its initial resemblance to allergic dermatitis, chronic pyoderma, or seborrheic conditions, means that many dogs undergo multiple rounds of treatment for presumed benign conditions before the malignant nature of their skin disease is recognized.

Cutaneous lymphoma in dogs is classified into two major forms based on the behavior of the malignant lymphocytes within the skin. Epitheliotropic cutaneous lymphoma, also known as mycosis fungoides, involves malignant T-lymphocytes that demonstrate a specific affinity for the epidermis, the outermost layer of skin. These abnormal cells accumulate within the epidermal layers, progressively replacing normal keratinocytes and disrupting skin function. Non-epitheliotropic cutaneous lymphoma involves lymphocytes that infiltrate the deeper dermis and subcutaneous tissues without the specific epidermal targeting seen in the epitheliotropic form. Both forms are serious diagnoses, but they differ in their clinical presentation, progression pattern, and therapeutic approach.

Understanding the clinical features of cutaneous lymphoma is important for all dog owners, not because the disease is common, but because early recognition and diagnosis can significantly improve the quality and duration of the affected dog's remaining life. Dogs that are diagnosed during the early patch or plaque stages of epitheliotropic lymphoma may benefit from treatments that control disease progression for extended periods, while dogs diagnosed at the advanced tumor stage generally have fewer therapeutic options and a more limited prognosis. This article provides a comprehensive overview of cutaneous lymphoma in dogs, including the warning signs that should prompt veterinary investigation, the diagnostic process, available treatments, and what to expect as the disease progresses.

Epitheliotropic Cutaneous Lymphoma (Mycosis Fungoides)

Patch Stage

The earliest stage of epitheliotropic lymphoma, the patch stage, produces flat areas of erythema (redness), scaling, and mild hair loss that are virtually indistinguishable from common allergic dermatitis or superficial pyoderma. The patches may be localized or multifocal, and they can wax and wane in severity, further reinforcing the misdiagnosis of an inflammatory condition. Some dogs show mild pruritus (itchiness) during this stage, while others appear completely comfortable. The patch stage can persist for months to years, and early skin biopsies may show only non-specific inflammation because the malignant lymphocyte population is sparse and difficult to distinguish from reactive inflammatory cells.

Plaque Stage

As the disease progresses, the patches thicken into raised plaques that are more easily palpable during physical examination. The plaques are firm, well-demarcated, and may be pink, red, or depigmented. Alopecia becomes more pronounced, and the affected skin may develop a scaly, thickened texture. At this stage, the malignant lymphocyte population has expanded sufficiently to be more readily detected on skin biopsy, and the characteristic pattern of epidermotropism, where lymphocytes preferentially cluster within the epidermal layers, becomes more apparent histopathologically. The plaque stage represents a critical diagnostic window, as treatment initiated at this point may achieve the best disease control.

Tumor Stage

The advanced tumor stage is characterized by the development of raised, nodular masses that may ulcerate, bleed, and become secondarily infected. These tumors can develop from preexisting plaques or arise de novo in previously normal skin. The tumors range from small, firm nodules to large, disfiguring masses, and multiple tumors may be present simultaneously. By the tumor stage, the malignant cells have typically expanded beyond the epidermis into the dermis and may involve regional lymph nodes or other organs. Dogs at this stage often show systemic signs including lethargy, decreased appetite, and weight loss, reflecting the advanced nature of the disease.

Mucocutaneous Involvement

Epitheliotropic lymphoma can involve the mucocutaneous junctions, which are the transition zones between skin and mucous membranes at the lips, eyelids, nostrils, anus, vulva, and prepuce. Involvement of these areas produces erythema, depigmentation, erosion, and ulceration that may be confused with autoimmune diseases such as pemphigus or lupus. Oral involvement, including ulceration of the hard palate, gums, and tongue, occurs in a subset of cases and can cause pain, difficulty eating, and excessive drooling. The combination of skin and mucocutaneous lesions is an important diagnostic clue that should prompt consideration of cutaneous lymphoma.

Non-Epitheliotropic Cutaneous Lymphoma

Clinical Features

Non-epitheliotropic cutaneous lymphoma presents differently from the epitheliotropic form, typically appearing as multiple dermal or subcutaneous nodules rather than the diffuse skin changes of mycosis fungoides. The nodules may be firm or soft, well-defined or poorly marginated, and can occur anywhere on the body. They may be solitary or numerous, ranging from a few millimeters to several centimeters in diameter. The overlying skin may be normal in appearance, alopecic, or ulcerated, depending on the size and depth of the nodule. Some dogs present with generalized skin thickening and erythema rather than discrete nodules.

Relationship to Systemic Lymphoma

Non-epitheliotropic cutaneous lymphoma may represent primary cutaneous disease or secondary cutaneous involvement by systemic multicentric lymphoma. Primary cutaneous lymphoma is confined to the skin at the time of diagnosis, while secondary cutaneous lymphoma indicates that the skin is one of several organs affected by a more widespread disease process. Distinguishing between these two scenarios is important because primary cutaneous lymphoma generally has a more protracted course, while secondary cutaneous involvement from multicentric lymphoma often indicates advanced systemic disease with a poorer prognosis.

Diagnostic Considerations

Diagnosis of non-epitheliotropic cutaneous lymphoma requires histopathological examination of biopsy specimens, as the discrete nodular presentation can mimic other skin tumors. Immunohistochemistry is typically performed on the biopsy sample to characterize the lymphocyte population and determine whether the cells are T-cells or B-cells, as this distinction has therapeutic and prognostic implications. B-cell cutaneous lymphoma may have a somewhat better prognosis than T-cell forms. Full staging with complete blood count, serum biochemistry, abdominal ultrasound, and thoracic radiographs helps determine whether the disease is confined to the skin or has systemic involvement.

Cutaneous Lymphoma in Dogs veterinary guide

Diagnostic Challenges and Workup

Why Early Diagnosis Is Difficult

The diagnostic challenge of cutaneous lymphoma lies in its ability to mimic common, benign skin conditions during the early stages. Veterinary dermatologists report that dogs with cutaneous lymphoma have often been treated for allergic dermatitis, chronic bacterial or fungal infection, or seborrhea for 6 to 18 months before the correct diagnosis is established. Early skin biopsies may be non-diagnostic because the malignant lymphocyte population is sparse, the cells may not yet show obvious atypical features, and the biopsy pathologist may interpret the findings as non-specific inflammation. Multiple sequential biopsies from the same patient over time may be necessary before the diagnostic pattern becomes clear.

Biopsy and Histopathology

Definitive diagnosis of cutaneous lymphoma requires skin biopsy with histopathological examination. Multiple biopsies from different lesion types (patches, plaques, and tumors if present) improve diagnostic yield. The pathologist looks for the characteristic pattern of lymphocytic infiltration, with epidermotropism being the hallmark of the epitheliotropic form. Pautrier microabscesses, which are clusters of atypical lymphocytes within the epidermis, are a classic but not always present histopathological finding. Immunohistochemistry identifies the phenotype (T-cell vs B-cell) and may include markers such as CD3 (T-cell), CD20 (B-cell), and CD8 or CD4 that further characterize the malignant population.

Complete Staging

Once cutaneous lymphoma is confirmed, staging evaluation determines the extent of disease and guides treatment planning. A complete blood count may reveal circulating atypical lymphocytes (leukemic phase, known as Sezary syndrome), particularly in advanced epitheliotropic disease. Serum biochemistry evaluates organ function. Lymph node aspirates from enlarged peripheral lymph nodes assess regional spread. Thoracic radiographs and abdominal ultrasound evaluate for visceral involvement. Bone marrow aspirate may be performed in advanced cases. The staging results inform prognosis and help the oncologist select the most appropriate treatment approach.

Treatment Options

Retinoids

Synthetic retinoids, particularly isotretinoin and acitretin, have demonstrated efficacy in managing epitheliotropic cutaneous lymphoma, particularly during the patch and plaque stages. These medications modulate keratinocyte differentiation and proliferation and have direct effects on malignant T-lymphocytes. Response rates of 40% to 50% have been reported, with some dogs achieving partial or complete clinical remission lasting months to over a year. Retinoids are generally well-tolerated, with the most common side effects including keratoconjunctivitis sicca (dry eye), hepatotoxicity, and gastrointestinal upset, all of which require regular monitoring during treatment.

Chemotherapy Protocols

Various chemotherapy protocols have been evaluated for canine cutaneous lymphoma, with variable response rates and duration of response. Lomustine (CCNU) is one of the most commonly used chemotherapy agents for this condition, with reported response rates of approximately 60% to 80%. However, responses are often partial and temporary, with most dogs experiencing disease progression within 3 to 6 months of initiating treatment. Combination chemotherapy protocols may improve response duration in some cases. Potential side effects of chemotherapy include myelosuppression (decreased blood cell production), gastrointestinal toxicity, and hepatotoxicity.

Radiation and Supportive Care

Localized radiation therapy can provide effective palliation of individual tumors or plaques that are causing particular discomfort. Radiation is especially useful for lesions in sensitive locations such as the face, mucocutaneous junctions, or areas prone to secondary infection. Supportive care measures, including topical therapy for secondary infections, nutritional support, pain management, and regular bathing to remove scale and maintain skin comfort, play an important role in maintaining quality of life throughout the disease course. Many dogs benefit from a combination of disease-directed therapy and comprehensive supportive care.

Prognosis and Quality of Life

Factors Affecting Survival

The prognosis for canine cutaneous lymphoma depends on several factors, including the form of disease (epitheliotropic vs non-epitheliotropic), the stage at diagnosis, the extent of body surface involvement, and the response to initial treatment. Dogs diagnosed during the patch or early plaque stage of epitheliotropic lymphoma may survive 1 to 3 years with appropriate treatment, while those diagnosed at the tumor stage typically have survival times of 3 to 6 months. Non-epitheliotropic B-cell cutaneous lymphoma may have a somewhat more favorable prognosis than T-cell forms.

Quality of Life Assessment

Throughout the management of cutaneous lymphoma, quality of life assessment should guide all treatment decisions. Many owners find it helpful to use a structured quality of life scoring system that evaluates factors such as appetite, comfort, mobility, hygiene, happiness, and the balance between good days and bad days. The goal of treatment is to maintain a good quality of life for as long as possible, and treatment should be adjusted or discontinued if side effects outweigh benefits. Open, ongoing communication between the owner and veterinary team ensures that the dog's wellbeing remains the central focus of the management plan.

While cutaneous lymphoma is a serious and generally incurable diagnosis, many dogs can enjoy months to years of good-quality life with appropriate management. The key is early diagnosis, realistic expectations, and a treatment approach that prioritizes the dog's comfort and quality of life. Working with a veterinary oncologist provides access to the latest treatment options and the expertise needed to navigate the complexities of this challenging disease.

When to Suspect Cutaneous Lymphoma

Certain clinical patterns should raise suspicion for cutaneous lymphoma and prompt more aggressive diagnostic investigation. Chronic skin disease that fails to respond to standard treatments for allergies, pyoderma, or seborrhea should be evaluated with skin biopsy, even if a previous biopsy was non-diagnostic. Skin lesions that progressively worsen despite appropriate therapy, or that initially improve but then plateau or advance, deserve reassessment. The development of raised plaques or nodules within previously flat, inflammatory skin lesions is particularly concerning for progression from the patch to plaque or tumor stage.

Dogs that develop depigmentation and erosion of mucocutaneous junctions, particularly involving the lips, eyelids, and nasal planum, should be evaluated for both autoimmune disease and cutaneous lymphoma. The combination of generalized erythroderma (diffuse skin redness) with lymphadenopathy (enlarged lymph nodes) is another important warning sign. Any dog over 8 years of age with chronic, progressive, treatment-resistant skin disease should have cutaneous lymphoma on the differential diagnosis list. Requesting consultation with a veterinary dermatologist can be invaluable for navigating the diagnostic challenges of this condition.

Supporting skin comfort during treatment?

Dogs with cutaneous lymphoma often benefit from topical care to manage secondary infections and maintain skin hygiene. Our Chlorhexidine Spray provides gentle antimicrobial support for compromised skin surfaces.

Shop Chlorhexidine Spray

Cutaneous Lymphoma in Dogs FAQ

Q: Is cutaneous lymphoma the same as systemic lymphoma?

No. Cutaneous lymphoma is a distinct form that primarily affects the skin, while systemic (multicentric) lymphoma primarily involves the lymph nodes and internal organs. However, advanced cutaneous lymphoma can spread to involve lymph nodes and organs, and systemic lymphoma can occasionally produce secondary skin lesions. The treatment approach and prognosis differ between these forms, making accurate classification important.

Q: How long can a dog live with cutaneous lymphoma?

Survival time varies considerably based on the stage at diagnosis and response to treatment. Dogs diagnosed during the early patch or plaque stage of epitheliotropic lymphoma may survive 1 to 3 years with treatment. Dogs diagnosed at the advanced tumor stage typically survive 3 to 6 months. Some dogs respond well to therapy and maintain good quality of life for extended periods, while others progress more rapidly.

Q: Can cutaneous lymphoma be cured?

Cutaneous lymphoma is generally considered an incurable condition in dogs. Treatment is aimed at controlling disease progression, maintaining quality of life, and extending survival time. Some dogs achieve significant clinical improvement or even apparent remission with treatment, but relapse is expected over time. The goal of therapy is to maximize comfortable, good-quality time rather than to achieve cure.

Q: Why was my dog treated for allergies before being diagnosed with skin cancer?

Cutaneous lymphoma, particularly in its early patch stage, closely mimics common allergic dermatitis in appearance. The lesions may be red, scaly, mildly itchy, and distributed in areas typical of allergic disease. Early biopsies may show only non-specific inflammation because the malignant cell population is too sparse to detect definitively. It is not uncommon for dogs to receive months of allergy treatment before repeat biopsies reveal the true diagnosis. This is not a reflection of mismanagement but rather the inherent diagnostic challenge of early cutaneous lymphoma.

Q: What are the side effects of chemotherapy for cutaneous lymphoma in dogs?

Chemotherapy side effects in dogs are generally milder than those experienced by humans. The most common concerns include gastrointestinal upset (decreased appetite, nausea, occasional vomiting or diarrhea), myelosuppression (decreased white blood cell counts that increase infection risk), and hepatotoxicity (liver effects that require monitoring with blood tests). Hair loss is uncommon in most dog breeds. Your veterinary oncologist will monitor your dog closely during treatment and adjust the protocol as needed to minimize side effects.

Sources

Fontaine, J., Heimann, M., Day, M.J. (2010). Canine cutaneous epitheliotropic T-cell lymphoma: a review of 30 cases. Veterinary Dermatology, 21(3), 267-275.

Moore, P.F., Olivry, T. (2010). Cutaneous lymphoma in companion animals. Clinics in Dermatology, 28(2), 188-195.

de Lorimier, L.P. (2006). Updates on the management of canine epitheliotropic cutaneous T-cell lymphoma. Veterinary Clinics of North America: Small Animal Practice, 36(1), 213-228.

Laprais, A., Bhatt, M., Rueda, J., et al. (2019). Treatment with lomustine (CCNU) for epitheliotropic lymphoma in dogs: a retrospective study of 63 cases. Veterinary and Comparative Oncology, 17(3), 346-355.

Gross, T.L., Ihrke, P.J., Walder, E.J., Affolter, V.K. (2005). Skin Diseases of the Dog and Cat, 2nd ed. Blackwell Publishing. Chapter on lymphocytic neoplasms.

Chan, C.M., Frimberger, A.E., Moore, A.S. (2018). Clinical outcome and prognosis of dogs with histopathologically confirmed epitheliotropic lymphoma treated with lomustine. Vet Comp Oncol, 16(1), E153-E159.